IN2012DN01827A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01827A
IN2012DN01827A IN1827DEN2012A IN2012DN01827A IN 2012DN01827 A IN2012DN01827 A IN 2012DN01827A IN 1827DEN2012 A IN1827DEN2012 A IN 1827DEN2012A IN 2012DN01827 A IN2012DN01827 A IN 2012DN01827A
Authority
IN
India
Prior art keywords
adenoviral vectors
adenoviral
serotype
heterologous sequences
antigens
Prior art date
Application number
Inventor
Timothy P Mayall
Jeff Alexander
Original Assignee
Paxvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paxvax Inc filed Critical Paxvax Inc
Publication of IN2012DN01827A publication Critical patent/IN2012DN01827A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.
IN1827DEN2012 2009-07-31 2010-07-30 IN2012DN01827A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23061709P 2009-07-31 2009-07-31
PCT/US2010/043951 WO2011014794A1 (en) 2009-07-31 2010-07-30 Adenoviral-based vectors

Publications (1)

Publication Number Publication Date
IN2012DN01827A true IN2012DN01827A (en) 2015-06-05

Family

ID=43529721

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1827DEN2012 IN2012DN01827A (en) 2009-07-31 2010-07-30

Country Status (13)

Country Link
US (2) US8865182B2 (en)
EP (1) EP2459716B1 (en)
JP (1) JP5903045B2 (en)
KR (1) KR20120052369A (en)
CN (1) CN102549152B (en)
AU (1) AU2010278797A1 (en)
BR (1) BR112012008060A2 (en)
CA (1) CA2769752A1 (en)
ES (1) ES2603779T3 (en)
IN (1) IN2012DN01827A (en)
MX (1) MX2012001404A (en)
RU (1) RU2012107702A (en)
WO (1) WO2011014794A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012107702A (en) 2009-07-31 2013-09-10 Пэксвэкс, Инк. ADENOVIRUS VECTORS
CN103154021A (en) * 2010-08-16 2013-06-12 威斯特解剖及生物研究所 Universal influenza a vaccines
WO2012116280A2 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
CN102775469B (en) * 2011-05-12 2018-02-09 厦门大学 Epitope of influenza A virus nucleocapsid protein and application thereof
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
US20130189303A1 (en) * 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
EP2764013B1 (en) 2011-10-05 2022-01-26 GenVec, Inc. Adenoviral vectors and methods of use
US9617560B2 (en) 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
US9790519B2 (en) * 2012-05-29 2017-10-17 Genvec, Inc. Modified serotype 28 adenoviral vectors
US9676824B2 (en) * 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
RU2507258C1 (en) * 2012-08-21 2014-02-20 Общество с ограниченной ответственностью "НТфарма" Recombinant pseudo adenoviral particle based on human being adenovirus genome of 5-th serotype for induction of specific immunity to influenza virus a of h3n2 subtype and method of its use
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
ES2897659T3 (en) * 2013-09-03 2022-03-02 Georgia Tech Res Inst Thermally stable vaccine formulations, processes and microneedles including vaccine formulations
CA2941116A1 (en) 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
WO2016106178A1 (en) * 2014-12-24 2016-06-30 The Uab Research Foundation, Inc. Multitargeting onocolytic adenovirus, methods of use, and methods of making
CA2988654A1 (en) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Adenovirus polynucleotides and polypeptides
AU2017207448A1 (en) * 2016-01-15 2018-07-26 Etubics Corporation Methods and compositions for influenza vaccination
CN105567736B (en) * 2016-02-03 2020-03-20 河南农业大学 Construction and application of E3-deleted region replication complete type recombinant adenovirus type 4 vector system
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN107841513B (en) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 Broad-spectrum influenza vaccine based on M2e epitope
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112019013402A2 (en) * 2016-12-28 2020-03-03 Invvax, Inc. INFLUENCE VACCINES
CN107686843A (en) * 2017-09-11 2018-02-13 南方医科大学 A kind of expression vector and its construction method based on adenovirus AdC6
EP3697899A1 (en) * 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Replication competent adenoviral vectors
JP7229239B2 (en) * 2017-10-31 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Adenovirus vector and use thereof
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN109504801A (en) * 2018-11-22 2019-03-22 李越希 A kind of RPA method, its primer special and probe and purposes detecting 21 type adenovirus hominis
CN109504802A (en) * 2018-11-22 2019-03-22 李越希 A kind of RPA method, its primer special and probe and purposes detecting 11/55 type adenovirus hominis
CN109504800A (en) * 2018-11-22 2019-03-22 李越希 A kind of RPA method for detecting universal adenovirus hominis, its primer special and probe and purposes
CN111057685B (en) * 2019-07-27 2022-03-18 中国人民解放军军事科学院军事医学研究院 Replication type 4 adenovirus vector recombinant Marburg virus disease vaccine
CN111057716B (en) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 Single plasmid vector system for packaging recombinant human adenovirus type 4 and application thereof
CN113908265B (en) * 2020-07-10 2024-03-15 上海市公共卫生临床中心 Human type 4 and type 7 adenovirus attenuated live vaccine and application thereof
WO2023009264A1 (en) * 2021-07-26 2023-02-02 Think Therapeutics, Inc. Compositions for optimized influenza peptide vaccines
WO2023015276A1 (en) * 2021-08-06 2023-02-09 Theravax, Inc. Adenoviral vector-based vaccine for emerging viruses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
AU745951B2 (en) * 1997-08-05 2002-04-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New immunoprotective influenza antigen and its use in vaccination
EP1071805B1 (en) * 1998-04-24 2011-07-27 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
US7829329B2 (en) * 1998-04-24 2010-11-09 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
KR20020013464A (en) * 1998-08-27 2002-02-20 추후제출 Targeted adenovirus vectors for delivery of heterologous genes
JP2003534805A (en) * 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン Modified bovine adenovirus with altered affinity
ATE433491T1 (en) 2001-01-18 2009-06-15 Vlaams Interuniv Inst Biotech OLIGOMERIC COMPLEXES OF CHIMERIC PROTEINS WITH ENHANCED IMMUNOGENIC POTENTIAL
WO2003072703A2 (en) * 2002-02-05 2003-09-04 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
WO2004108755A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Chimeric adenovirus capsid proteins
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP2007532656A (en) * 2004-04-12 2007-11-15 アメリカ合衆国 Methods for inducing immune responses using adenoviral vectors
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US8926987B2 (en) * 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
WO2006063101A2 (en) * 2004-12-09 2006-06-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vaccines for the rapid response to pandemic avian influenza
JP2008541730A (en) * 2005-05-23 2008-11-27 ヴァクシン インコーポレイテッド A rapid method for the production of recombinant adenoviral vectors free of high titers and replication competent adenoviruses.
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
WO2007070392A2 (en) * 2005-12-12 2007-06-21 Canji, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
LT1988823T (en) 2006-02-09 2018-12-10 Genzyme Corporation Slow intraventricular delivery
EA014757B1 (en) * 2006-02-28 2011-02-28 Вэксарт, Инк. Chimeric adenoviral vector, immunogen composition based thereon, a method for eliciting an immune response using the vector and isolated nucleic acid
CN101437538A (en) 2006-04-28 2009-05-20 宾夕法尼亚州立大学托管会 Modified adenovirus hexon protein and uses thereof
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CA2658559A1 (en) 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP2059602A4 (en) * 2006-07-28 2010-06-23 Commw Scient Ind Res Org Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
CN101358202B (en) 2007-07-30 2011-02-09 中国农业科学院哈尔滨兽医研究所 Recombinant canine adenovirus type 2 transfer vector, construction method and application thereof
RU2012107702A (en) 2009-07-31 2013-09-10 Пэксвэкс, Инк. ADENOVIRUS VECTORS

Also Published As

Publication number Publication date
CN102549152A (en) 2012-07-04
CA2769752A1 (en) 2011-02-03
JP2013501001A (en) 2013-01-10
CN102549152B (en) 2015-11-25
RU2012107702A (en) 2013-09-10
ES2603779T3 (en) 2017-03-01
BR112012008060A2 (en) 2016-11-22
JP5903045B2 (en) 2016-04-13
AU2010278797A1 (en) 2012-03-15
WO2011014794A1 (en) 2011-02-03
EP2459716B1 (en) 2016-08-17
EP2459716A1 (en) 2012-06-06
MX2012001404A (en) 2012-06-01
KR20120052369A (en) 2012-05-23
US8865182B2 (en) 2014-10-21
US20110123564A1 (en) 2011-05-26
EP2459716A4 (en) 2013-06-19
US20150086579A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
IN2012DN01827A (en)
CY1119284T1 (en) PARTICULAR SUBJECTS WITH VIRUS-PROTEIN SOLUTIONS (VLPs)
MX2014006361A (en) Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof.
MX352604B (en) Hendra and nipah virus g glycoprotein immunogenic compositions.
IL208147A0 (en) Replication-defective flavivirus vaccines and vaccine vectors
MX347997B (en) Newcastle disease virus vectored avian vaccines.
MX2019006722A (en) Chimpanzee adenovirus constructs with lyssavirus antigens.
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
MX2013010620A (en) Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof.
MX344103B (en) Newcastle disease virus vectored herpesvirus vaccines.
NZ628213A (en) Adenoviruses expressing heterologous tumor-associated antigens
WO2011130627A3 (en) Chimpanzee adenoviral vector-based filovirus vaccines
EP2525816A4 (en) Targeted heterologous antigen presentation on calicivirus virus-like particles
WO2013052859A3 (en) Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
WO2012065105A3 (en) Chimeric flavivirus vaccines
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
WO2011119716A3 (en) Flavivirus host range mutations and uses thereof
WO2010048394A3 (en) Vaccine against african horse sickness virus
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
CO6670515A2 (en) Parapoxvirus Vectors
ZA201007880B (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
EP2504029A4 (en) Compositions, methods and uses for expression of enterobacterium-associated peptides
WO2009076542A3 (en) Vaccine directed against adenovirus serotype 14
MX2010008170A (en) Canine influenza vaccines.